Sonoma Pharmaceuticals (SNOA) Total Current Liabilities (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Total Current Liabilities of $4.8 million for Q1 2026, up 17.97% year-over-year from $4.1 million in Q1 2025, and up 14.58% quarter-over-quarter from $4.2 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Total Current Liabilities (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Total Current Liabilities history runs 16 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 17.97% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (up 17.97% YoY), while the FY2026 annual figure was $4.8 million, up 17.97% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $4.8 million, up from $4.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $5.8 million in Q1 2022, with the low at $3.1 million in Q4 2023.
- The 5-year median for Total Current Liabilities is $3.9 million (2022), against an average of $4.1 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 42.69% in 2022, then tumbled 36.12% in 2023.
- Sonoma Pharmaceuticals' Total Current Liabilities stood at $3.9 million in 2022, then retreated by 21.86% to $3.1 million in 2023, then increased by 20.46% to $3.7 million in 2024, then gained by 13.88% to $4.2 million in 2025, then gained by 14.58% to $4.8 million in 2026.
- Business Quant data shows SNOA's Total Current Liabilities at $4.8 million in Q1 2026, $4.2 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.45 Mn |
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 4.22 Mn |
| Sep 30, 2025 | 4.32 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.10 Mn |
| Dec 31, 2024 | 3.70 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 3.75 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 30, 2023 | 3.24 Mn |
| Jun 30, 2023 | 4.04 Mn |
| Mar 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 3.93 Mn |
| Sep 30, 2022 | 3.53 Mn |
| Jun 30, 2022 | 4.85 Mn |
| Mar 31, 2022 | 5.82 Mn |
| Dec 31, 2021 | 3.88 Mn |
| Sep 30, 2021 | 4.08 Mn |